Certified by Founder Lodge 
                                        
                                        Nextech Invest
 
                                                 Switzerland  -  Zurich 
                                             INVESTOR 
                                            
                                                                                    1 Disclosed Funding Rounds $122,000,000
                                            51 Participating Investments
- 
                                                Operating Status 
                                                
Active
 - 
                                                Last Funding Type 
                                                
Seed
 - 
                                                Company Type 
                                                
For Profit
 - Website
 - Contact
 - Social Links
 
                                            Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. We focus almost exclusively on oncology therapeutics, and on helping to drive value
                                        
                                        
                                        
                                                                                
                                        
                                        
                                        
                                        
                                                                                
                                        | Company | Date | Round | Raised | 
|---|---|---|---|
   IDRx | 
                                                            August, 02 ,2022 | Series A | $122,000,000 | 
   Mariana Oncology | 
                                                            September, 08 ,2023 | Series B | $175,000,000 | 
   Flare Therapeutics | 
                                                            March, 23 ,2023 | Series B | $123,000,000 | 
   Mariana Oncology | 
                                                            September, 08 ,2023 | Series B | $175,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   IDRx | 
                                                            August, 02 ,2022 | Series A | $122,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Flare Therapeutics | 
                                                            March, 23 ,2023 | Series B | $123,000,000 | 
   Boundless Bio | 
                                                            May, 17 ,2023 | Series C | $100,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Boundless Bio | 
                                                            May, 17 ,2023 | Series C | $100,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Mariana Oncology | 
                                                            September, 08 ,2023 | Series B | $175,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Mariana Oncology | 
                                                            September, 08 ,2023 | Series B | $175,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Atavistik Bio | 
                                                            December, 26 ,2023 | Unknown | $40,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   FogPharma | 
                                                            March, 05 ,2024 | Series E | $145,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Delphia Therapeutics | 
                                                            May, 07 ,2024 | Series A | $67,000,000 | 
   Tubulis GmbH | 
                                                            October, 16 ,2025 | Series C | $359,197,300 | 
   Scorpion Therapeutics | 
                                                            July, 17 ,2024 | Series C | $150,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Tubulis GmbH | 
                                                            October, 16 ,2025 | Series C | $359,197,300 | 
                                                
  IDRx
  Mariana Oncology
  Flare Therapeutics
  Atavistik Bio
  Alterome Therapeutics, Inc
  Delphia Therapeutics
  Boundless Bio
  FogPharma
  Scorpion Therapeutics
  Alpha-9 Oncology
  Tubulis GmbH
Cherry Ventures
 
                                            
Blue Bear Capital
 
                                            
Slow Ventures
Climate Capital
Eniac Ventures
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                                                        
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)